The only significant (and positive) aspects of the report that I could see are that things are proceeding towards FDA submission as planned,
and:
"The Company has $38.3m USD in short-term investments in addition to the $44.0m cash and cash equivalents shown above. With $82.4m in cash and short-term investments, the Company has 10.8 quarters of funding available."
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
-0.005(0.47%) |
Mkt cap ! $323.5M | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.13 | $1.05 | $256.1K | 234.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8000 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 120133 | 1 |
View Market Depth
| Last trade - 15.58pm 28/06/2024 (20 minute delay) ? |
| EBR (ASX) Chart |